The Global Chemiluminescence Imaging Market is estimated to be valued at US$ 3391.7 Mn in 2022 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Chemiluminescence imaging techniques utilize light-emitting chemical reactions to visualize specific biomolecules and generate images with high sensitivity. This technology finds various applications in molecular biology research, clinical diagnostics, and forensic investigations by offering sensitive detection of multiple analytes.
Market Dynamics:
The growth of the global chemiluminescence imaging market is attributed to increasing research activities in the field of molecular biology and genomics. According to the Coalition for Health Funding report 2018, the U.S. National Institutes of Health invested around US$ 37.3 billion towards research projects in 2017, indicating rising R&D investments that demand enhanced visualization solutions.
Furthermore, product launches with improved features by industry players also supports the market growth. For instance, in 2022, Thermo Fisher Scientific launched Alexa Fluor DyLight reagents for chemiluminescent Western blot detection that provides 10x higher reagent sensitivity and signal-to-noise ratio compared to conventional HRP substrates.
Market key trends:
One of the key trends in the chemiluminescence imaging market is the increasing adoption of chemiluminescence imaging in pharmaceutical and biotechnology companies for drug discovery and development activities. Chemiluminescence imaging has emerged as a valuable technique for protein and nucleic acid detection during various stages of drug R&D such as target identification, lead optimization, preclinical and clinical development. Its high sensitivity and ability to detect multiple targets simultaneously makes it an attractive option compared to conventional fluorescence methods.
SWOT Analysis
Strength: Chemiluminescence offers high sensitivity detection and allows quantitative measurement over a wide range. It does not require an external light source for excitation process making the detection cost-effective.
Weakness: Chemiluminescence imaging has relatively low resolution and spatial information compared to fluorescence imaging. The signal lasts for a short duration requiring faster imaging.
Opportunity: Growing proteomics and next generation sequencing applications open up new areas for adoption of chemiluminescence imaging systems. Increasing R&D investments of pharmaceutical companies also present an opportunity.
Threats: Availability of superior fluorescence imaging technologies acting as alternatives can hamper the growth. Stringent regulations associated with product approval process increases time to market.
Key Takeaways:
The Global Chemiluminescence Imaging Market Demand was valued at USD 3391.7 Million in 2022. The market is expected to witness high growth, exhibiting a CAGR of 4.3% over the forecast period, due to increasing research activities in the area of drug discovery.
Regional analysis: North America dominated the global chemiluminescence imaging market in 2022 and is expected to maintain its lead over the forecast period. This can be attributed to presence of major market players and availability of extensive research infrastructure and funding for life science research in the region. Asia Pacific is anticipated to exhibit the fastest growth rate during the analysis period owing to rising investments by regional governments to support development of bioscience industries.
Key players: Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, General Electric, Azure Biosystems.
Key players operating in the chemiluminescence imaging market are Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, General Electric, Azure Biosystems. These players are focusing on new product launches and investments for business expansion to strengthen their market position.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian